Monday, September 10, 2018

Biodesy Finds $20M In Series C Funding

South San Francisco-based Biodesy, a developer of technology for biomolecule characterization, announced on Monday that it has raised $20M in a Series C funding round. The funding was led by Alexandria Venture Investments, and also included 5AM Ventures, Pfizer Ventures (PV) and Roche Venture Fund (RVF). As part of the funding, the company said it has named Ariel G. Notcovich as its new Chief Executive Officer. Notcovich was previously at Bio-Rad Laboratories, Inc. and also had been founder of ProteOptics Ltd. The company said the new funds will go to expand its scientific and commercial operations team, towards strategic partnerships, and other efforts.